Teva asks U.S. justices for stay in Copaxone case

By Lawrence Hurley WASHINGTON (Reuters) - Teva Pharmaceutical Industries on Monday asked the U.S. Supreme Court to stay an appeals court ruling that would strip its $4 billion-a-year multiple sclerosis drug Copaxone of its patent protection in 2014 rather than 2015. In July, the U.S. Court of Appeals for the Federal Circuit issued its decision in a patent fight that pits Teva against two teams developing cheaper generic forms of Copaxone: one with Novartis AG and Momenta Pharmaceuticals Inc and another between Mylan Inc and Natco Pharma Ltd. The appeals court upheld some of nine patents involved in the drug, or portions thereof, but declared several invalid, shortening patent protection for the drug.



via Health News Headlines - Yahoo! News http://news.yahoo.com/teva-asks-u-justices-stay-copaxone-case-211836411--finance.html